Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Benzonatate · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Benzonatate 200 mg | EXPERIMENTAL | - |
| Benzonatate 800 mg | EXPERIMENTAL | - |
| Moxifloxacin 400 mg | ACTIVE_COMPARATOR | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Benzonatate | EXPERIMENTAL | Benzonatate Active |
| Name | Type | Description |
|---|---|---|
| Benzonatate 200 mg | DRUG | 2 benzonatate 100 mg perles and 6 placebo perles give by mouth once |
| Benzonatate 800 mg | DRUG | 8 benzonatate 100 mg perles given by mouth once |
| Moxifloxacin 400 mg | DRUG | 1 moxifloxacin 400 mg tablet given by mouth once |
| Placebo | DRUG | 8 placebo perles given by mouth once |
| Benzonatate - 400 mg | DRUG | Benzonatate - 400 mg single dose |
| Benzonatate - 600 mg | DRUG | Benzonatate - 600 mg single dose |
Inclusion Criteria: * Healthy male and female subjects between the ages of 18 and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12- lead ECG an...
Benzonatate is a small molecule being studied for use in cough and in healthy volunteers. It is currently in Phase 1 clinical development. Benzonatate is being developed by Pfizer, Inc. (NYSE: PFE).
Benzonatate is a small molecule in development for respiratory conditions, specifically cough. Its molecular target has not been disclosed in available clinical trial information. The drug is being evaluated in Phase 1 studies.
Benzonatate is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 1 clinical development for cough and healthy volunteer studies.
Benzonatate is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. Two Phase 1 trials have been completed, both in the United States.
Benzonatate has been studied in two completed Phase 1 clinical trials. NCT01690975 was a dose tolerance study in cough with 9 participants. NCT02207699 evaluated the effect of Benzonatate on QT intervals in 68 healthy volunteers. Both trials were conducted in the United States.
Benzonatate is not listed under any alternative names in the available clinical trial information. It is being studied under the name Benzonatate in Phase 1 trials for cough and healthy volunteer studies.